.Contending enthusiasms.R.S., M.S., H.G. as well as A.A.R. are actually coordinators of the 1M1M initiative.
H.G. as well as A.A.R. are actually panel of supervisors participants and R.S., M.S.
and also A.A.R. are actually members of the medical consultatory board of N1C. A.A.R.
makes known work through LUMC, which possesses patents on exon-skipping innovation, several of which has actually been licensed to BioMarin and subsequently sublicensed to Sarepta. As co-inventor of some of these patents, A.A.R. was allowed to an allotment of royalties.
A.A.R. better reveals serving as specialist for PTC Therapeutics, Sarepta Therapies, Regenxbio, Dyne Therapeutics, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and also Astra Zeneca. Before 5 years, A.A.R.
additionally executed consulting with for Alpha Anomeric. A.A.R. also reports registration of the scientific advisory boards of Eisai, Hybridize Rehabs, Silence Therapies, Sarepta Therapies, Sapreme and also Mitorx.
In the past 5 years, A.A.R. was actually also a clinical board of advisers member for ProQR. Pay for A.A.R.
u00e2 s consulting as well as advising tasks is actually paid to LUMC. Previously 5 years, LUMC additionally acquired audio speaker gratuity coming from PTC Rehabs, Alnylam Netherlands, Italfarmaco and also Pfizer and financing for contract investigation coming from Sapreme, Eisai, Galapagos, Synaffix as well as Alpha Anomeric. Project funding is actually gotten coming from Sarepta Rehabs and also Entrada via unlimited grants.
H.G. has nothing to reveal in connection with the subject matters covered in this document. Before 5 years, he has actually likewise acquired consultancy honoraria coming from UCB.
M.S. received consultancy honoraria coming from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly as well as Solaxa before 5 years, all unrelated to the present document. R.S.
possesses nothing to divulge in connection with the subject matters covered in this particular manuscript. She has received sound speaker and/or consultancy honoraria or even funding additions coming from Abbvie, Bial, STADA and also Everpharma over the last 5 years.